The FDA granted Breakthrough Device designation to Natera's cell-free DNA multi-cancer early detection assay. What it means for primary care.
Opinion|Videos|January 29, 2025
Thyroid Hormone Monitoring and Patient Surveillance
Author(s)Todd W. Frieze, MD
Todd W. Frieze, MD, highlights the various ways to accurately assess patient thyroid hormone levels and the general guidelines on patient surveillance.
Advertisement
Advertisement
Related to this article
Most adolescents with sporadic colorectal cancer present with stage III or IV disease, and few have a family history, per data presented at AAP 2026.
Freenome reports 18.2% sensitivity for advanced precancerous lesions and 80.4% for colorectal cancer with its updated blood screening test.
FDA approves olanzapine, a once-monthly subcutaneous injection for adults with schizophrenia, boosting symptom control while reducing monitoring needs and highlighting weight risks.
The CardioGuide HF app from Abbott will show patients their pulmonary artery pressure trends and deliver medication instructions set by their care teams.
FDA has granted IDE approval for the STROKE-REWIRE pivotal trial evaluating NeuWire Medical's neurostimulation device for chronic ischemic stroke recovery.
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
EASD 2026: Oral semaglutide users lost 4.1% of body weight 3 months after switching from injections in an observational study without a comparator group.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Grants Breakthrough Device Designation to Natera's Multi-Cancer Early Detection Blood Test
2
Building Clinician Confidence to Prescribe HIV PrEP in Primary Care
3
PrEP Deserts: Why HIV Prevention Still Misses Those at Risk
4
Most Adolescents With Colorectal Cancer Diagnosed at Advanced Stage, Study Finds
5